| 20th week of 2009 patent applcation highlights (05-14-09/05-14-09_49) part 49 |
| Patent application number | Title | Published |
|---|
| 20090124619 | NOVEL COMPOUNDS - This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted morpholines and piperidines, according to Formula I | 05-14-2009 |
| 20090124620 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR - The present invention relates to an inhibitor of plasminogen activator inhibitor-1. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. Furthermore, the present invention relates to a novel compound having PAI-1 inhibitory activity represented by the following general formula (I), and a salt thereof. | 05-14-2009 |
| 20090124621 | PYRAZOLE DERIVATIVES AS KINASE INHIBITORS - The present invention provides compounds having the general structure I, or a pharmaceutically acceptable salt thereof: | 05-14-2009 |
| 20090124622 | Medicament Containing a Thiazole Derivative as an Active Ingredient - A prophylactic and/or therapeutic agent for sinusitis, nasal obstruction•nasal mucosa congestion containing N-{2-[2-[(3-fluorophenyl)imino]-4-(4-morpholin-4-ylphenyl)-1,3-thiazol-3(2H)-yl]ethyl}-N′-methylurea represented by the formula (1) or its pharmaceutically acceptable salt as an active ingredient. | 05-14-2009 |
| 20090124623 | METHODS FOR PRESERVING AND/OR INCREASING RENAL FUNCTION USING XANTHINE OXIDOREDUCTASE INHIBITORS - The present invention relates to methods of preserving or increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. The present invention also relates to methods of increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. | 05-14-2009 |
| 20090124624 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF - The invention concerns 1-amino-phthalazine derivatives of general formula (I): | 05-14-2009 |
| 20090124625 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS - The present invention relates to novel compounds of formula (I) wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors. | 05-14-2009 |
| 20090124626 | Pharmaceutical agent comprising insulin resistance improving agent - To provide a method for treating diabetes which has an excellent hypoglycemic action and causes minimal adverse drug reactions, there is provided a medicine comprising a DPP-IV inhibitor and an insulin sensitizer in combination. | 05-14-2009 |
| 20090124627 | COMPOSITIONS FOR SLEEPING DISORDERS - Provided herein is a method for treating, preventing, or ameliorating a disorder such as insomnia or another sleeping disorder using a composition that contains an effective amount of one or more compounds. | 05-14-2009 |
| 20090124628 | 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments - The present invention relates to new 2-benzylaminodihydropteridinones of general formula (I) | 05-14-2009 |
| 20090124629 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS - The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: | 05-14-2009 |
| 20090124630 | 3, 4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AS SELECTIVE DOPAMINE D3 LIGANDS - The invention relates to 3,4-dihydro-2-naphthamide derivatives of formula (I), pharmaceutical compositions containing them and their therapeutic applications as partial agonists or antagonists of the dopamine D3 receptor for the treatment of neuropsychological disorders. | 05-14-2009 |
| 20090124631 | Combination Therapy - The invention relates to the treatment of mammalian diseases manifested by abnormal cell growth and/or abnormal cell proliferation. More particularly, the invention relates to the use of combination therapies to control abnormal cell growth and/or abnormal cell proliferation. In particular, the invention relates to the use of isotype-selective inhibitors of histone deacetylases 1, 2 and/or 3 (HDACs 1-3), as well as isotype-selective inhibitors of HDAC1 and/or HDAC2, to potentiate therapeutic activity of microtubule-stabilization agents. | 05-14-2009 |
| 20090124632 | Methods and kits related to the topical administration of quinolone antibiotics.degree. - The present invention is generally directed to the treatment of dermatological bacterial infections, burns and wounds. It is more specifically directed to the treatment of such infections, burns and wounds using one or more quinolone antibiotics. In one method of treatment aspect, an aqueous solution containing Ciprofloxacin-HCl is topically applied to the skin of a patient exhibiting a dermatological disorder. In another method of treatment aspect, an ointment containing Ciprofloxacin-HCl is topically applied to the skin of a patient exhibiting a dermatological disorder. | 05-14-2009 |
| 20090124633 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES - The present invention relates to heterocyclic substituted N-Oxides of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. | 05-14-2009 |
| 20090124634 | Novel dipodazine compounds and applications - The invention relates to a novel class of dipodazine derivatives, suitable for use as surface on-growth inhibiting agents. | 05-14-2009 |
| 20090124635 | CHEMICAL COMPOUNDS - The present invention provides compounds of formula (I) wherein R | 05-14-2009 |
| 20090124636 | CHEMICAL COMPOUNDS - The present invention provides compounds of formula (I) wherein R | 05-14-2009 |
| 20090124637 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 - There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) [Chemical formula should be inserted here. Please see paper copy] wherein R | 05-14-2009 |
| 20090124638 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES - The present invention provides anti-inflammatory compounds useful in the treatment of diseases and conditions in which inflammation is involved in disease progression or the manifestation of symptoms of the disease or condition. | 05-14-2009 |
| 20090124639 | VALACYCLOVIR FORMULATIONS - The present invention relates to valacyclovir formulations having improved bioavailability resulting in better efficacy and/or requiring less frequent administration. | 05-14-2009 |
| 20090124640 | Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor - The present invention relates to a new compound A: [Chemical formula should be inserted here. Please see paper copy] a process for its preparation, pharmaceutical formulations containing said therapeutically active compound and to the use of said active compound in therapy. The compound is an inhibitor of the enzyme MPO and is thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders. | 05-14-2009 |
| 20090124641 | Mitotic Kinesin Inhibitors - The present invention relates to fluorinated 2-aminomethylquinazolinone derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals. | 05-14-2009 |
| 20090124642 | Crystalline forms of Erlotinib HCI and formulations thereof - The invention provides a novel crystalline form of Erlotinib HCl, processes for its preparation, and formulations thereof. | 05-14-2009 |
| 20090124643 | Use of a Cannabinoid CB1 Receptor Antagonist for Preparation of Drugs Useful for the Prevention and Treatment of Benign Prostatic Hypertrophy - The present invention relates to the use of cannabinoid CB1 receptor antagonist for the preparation of drugs useful for the prevention and treatment of benign prostatic hypertrophy. | 05-14-2009 |
| 20090124644 | HIV INHIBITING 2-(4-CYANOPHENYLAMINO) PYRIMIDINE DERIVATIVES - HIV replication inhibitors of formula | 05-14-2009 |
| 20090124645 | Novel Pyrimidine-2,4-Diamine Derivatives and their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels - This invention relates to novel pyrimidine-2,4-diamine derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 05-14-2009 |
| 20090124646 | SUBSTITUTED INDOLYL ALKYL AMINO DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 05-14-2009 |
| 20090124647 | Indole Derivatives as Antitumoral Compounds - Antitumoural compounds of general formula (I); wherein Ar is an heterocyclic group of formula (a) and R | 05-14-2009 |
| 20090124648 | Synthesis and Crystalline Forms of Npy5 Antagonist - The present invention relates to a process for producing crystalline trans-N-[1-(2-fluorophenyl)-S-pyrazoly]-3-ox-ospiro[6-azaisobenzofuran-1(3H),1′-cyclohexane]-4′-carboxamide and novel salts, hydrates and polymorphs thereof. | 05-14-2009 |
| 20090124649 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES - The present invention provides a compound of Formula I or Formula II: | 05-14-2009 |
| 20090124650 | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol - The invention pertains to a method of using oxymorphone in the treatment of pain by providing a patient with an oxymorphone dosage form and informing the patient or prescribing physician of the effect of alcohol on the maximum concentration of oxymorphone. | 05-14-2009 |
| 20090124651 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF - The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy. | 05-14-2009 |
| 20090124652 | Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate - The invention provides various crystalline forms of 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate, pharmaceutical compositions, methods of making, and methods of use. | 05-14-2009 |
| 20090124653 | Muscarinic Acetylcholine Receptor Antagonists - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 05-14-2009 |
| 20090124654 | Aryl and Heteroaryl Compounds, Compositions, Methods of Use - This invention provides aryl and heteroaryl compounds of formula (X). The compounds of the invention may be useful as antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be used to inhibit the intrinsic pathway of blood coagulation. Formula (X) wherein R | 05-14-2009 |
| 20090124655 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS - The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 05-14-2009 |
| 20090124656 | Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them - Compounds of formula (I): | 05-14-2009 |
| 20090124657 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONTELUKAST - Pharmaceutical compositions comprising montelukast or pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof. | 05-14-2009 |
| 20090124658 | Treatments for Viral Infections - The present invention relates to improved methods and compositions for treating viral infections and other diseases and conditions that induce a cytokine storm. More particularly, the present invention relates to novel compositions comprising quercitin, and an anti-convulsant, such as phenyloin, in combination with multivitamins as an anti-viral composition and methods of use thereof. | 05-14-2009 |
| 20090124659 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors - The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine. | 05-14-2009 |
| 20090124660 | Piperidine Compounds Useful as Malonyl-CoA Decarboxylase Inhibitors - The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity. | 05-14-2009 |
| 20090124661 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. | 05-14-2009 |
| 20090124662 | Migrastatin analogs in the treatment of cancer - In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and/or ovarian tumor metastasis. | 05-14-2009 |
| 20090124663 | Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors - This invention relates to novel N-phenyl-piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 05-14-2009 |
| 20090124664 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them - The present invention relates to selected (R)-arylalkylamino derivatives of formula (I), in which R, R1 and Ar are as defined in the claims. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion. | 05-14-2009 |
| 20090124665 | Potassium Channel Inhibitors - The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like. | 05-14-2009 |
| 20090124666 | TRPV1 ANTAGONISTS - Compounds of formula (I) | 05-14-2009 |
| 20090124667 | Novel Dual-Use Peptidase Inhibitors as Prodrugs for a Therapy of Inflammatory and Other Diseases - Compounds of the general formulae (1) and (2) | 05-14-2009 |
| 20090124668 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY - The present application describes modulators of MCP-1 of formula (I): | 05-14-2009 |
| 20090124669 | Structural Analogues of Avenanthramides, Their Use in Compositions Useful in the Treatment of Dermatological Disorders - Novel compounds for the prevention and treatment of dermatological disorders with an immunoallergic, hyperproliferative and inflammatory component, and a method of producing such compounds. The compounds are bioisosteres of substances with avenanthramide structures. | 05-14-2009 |
| 20090124670 | METHOD FOR DESIGNING FORMULATION OF SELF-EMULSIFYING PREPARATION - The present invention provides a High Throughput Formulation Screening system for quickly preparing and evaluating, at low cost, a Self-Emulsifying Drug Delivery System formulation containing ingredients in a viscous liquid state or in a semi-solid or solid state. More specifically, the present invention provides a method for formulation designing of a self-emulsifying preparation, including the steps of: diluting, in a diluent solvent, each of the ingredients in a viscous liquid state or in a semi-solid or solid state to prepare each dilution containing the constituent ingredient; and preparing plural test mixtures by dispensing the ingredients contained in the dilutions and ingredients other than those ingredients into plural test vessels so that the kinds and mixed amounts of the ingredients and the other ingredients added differ among the test vessels. | 05-14-2009 |
| 20090124671 | TRPV1 ANTAGONISTS - The present invention relates to compounds of formula (I) | 05-14-2009 |
| 20090124672 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS - Disclosed are isoflavone derivatives having the structure of Formula I | 05-14-2009 |
| 20090124673 | Method for treating diabetic nephropathy - Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: | 05-14-2009 |
| 20090124674 | Method for treating congestive heart failure - Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: | 05-14-2009 |
| 20090124675 | INHIBITORS OF ANTI-APOPTOTIC PROTEINS - Various compounds comprising a thiazolidine ring are described as well as the use of such compounds to inhibit at least one BCL-2 protein family member. One of the compounds described has the structure the structure A, | 05-14-2009 |
| 20090124676 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY - Disclosed herein are compounds having a formula: | 05-14-2009 |
| 20090124677 | Method For Obtaining A Pharmaceutically Active Compound (Irbesartan) And Its Synthesis Intermediate - It is provided a method for obtaining Irbesartan polymorph A, with few synthesis steps, by coupling the intermediate of formula (II) with the compound of formula (III), neutralising one of its alkaline salts in an aqueous medium and recrystallising the crude product obtained. The utilisation of said method obviates protection and deprotection of the tetrazole ring and is therefore of considerable interest for obtaining Irbesartan on a large industrial scale. The invention also refers to the synthesis intermediate of formula (II). | 05-14-2009 |
| 20090124678 | Combined Use of Metconazole and Epoxiconazole for Reducing or Preventing the Contamination of Cereals With Mycotoxins - The invention relates to the combined use of metconazole and epoxiconazole for reducing or preventing the contamination of cereals with mycotoxins formed by mould fungus producing trichothecene. | 05-14-2009 |
| 20090124679 | Agricultural or Horticultural Bactericide Composition and Method of Controlling Plant Disease - The present invention provides a fungicide composition having stable and high harmful bio-organism control effect on crop plants infected with plant diseases due to plant diseases. Specifically, the present invention provides a fungicide composition for agricultural or horticultural use, which comprises: (a) an indole compound represented by formula (I): | 05-14-2009 |
| 20090124680 | USE OF PRODRUG COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR MANUFACTURE OF MEDICAMENT FOR TREATMENT OR PREVENTION OF DISEASES INVOLVING METABOLIC SYNDROME - Provided is a use of a prodrug composition containing a naphthoquinone-based compound of Formula 1 for the manufacture of a medicament for treatment or prevention of metabolic syndrome diseases. | 05-14-2009 |
| 20090124681 | BETA-LACTONE COMPOUNDS - The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: | 05-14-2009 |
| 20090124682 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity - A compound of the formula (1) or a pharmaceutically-acceptable salt: (A chemical formula should be inserted here—please see paper copy enclosed herewith) (1) possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described. | 05-14-2009 |
| 20090124683 | MERCAPTAN AND SELENO-MERCAPTAN COMPOUNDS AND METHODS OF USING THEM - Novel mercaptan compounds, particularly those including a photolabile protecting group, are described as well as methods of using the compounds for the prevention and treatment of ocular damage and disease. | 05-14-2009 |
| 20090124684 | Stimulation Of CPT-1 As A Means To Reduce Weight - This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for development of therapeutics that selectively enhance fatty acid oxidation, increase energy production, and reduce adiposity while preserving lean mass, through the pharmacological stimulation of CPT-1 activity. In a preferred mode, the agent is administered in an amount sufficient to increase fatty acid oxidation. In another preferred mode, the agent is administered in an amount sufficient to antagonize malonyl CoA inhibition of CPT-1. In yet another preferred mode, the agent is administered in an amount sufficient to increase malonyl CoA level. | 05-14-2009 |
| 20090124685 | AGAVE SYRUP EXTRACT HAVING ANTICANCER ACTIVITY - The present invention comprises an | 05-14-2009 |
| 20090124686 | GSK-3 INHIBITORS - The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3β, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus. | 05-14-2009 |
| 20090124687 | Benzofuran Compound and Pharmaceutical Composition Containing the Same - The present invention relates to a compound having a leukotriene (particularly leukotriene B4) inhibitory action, and useful for the prophylaxis or treatment of diseases such as allergy, asthma, inflammation, cancer and the like. | 05-14-2009 |
| 20090124688 | Prostaglandin reductase inhibitors - A method of inhibiting 15-keto prostaglandin-Δ | 05-14-2009 |
| 20090124689 | CETP Inhibitors - Compounds having a biphenyl group substituted with a phenyl or heteroaromatic group, as shown in Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: | 05-14-2009 |
| 20090124690 | Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins - The present invention relates to, in part, novel sulfate and bisphenol compounds useful for the recognition, attachment and growth of unwanted biologics on natural and manmade surfaces. Another aspect of the invention relates to combinatorial libraries for producing the same. Another aspect of the invention relates to pharmaceutical formulations comprising the same. | 05-14-2009 |
| 20090124691 | INHIBITOR OF INCREASE IN POSTPRANDIAL BLOOD INSULIN LEVEL - The present invention provides an agent for inhibiting a postprandial increase in blood insulin level, wherein the agent containing a monoacylglycerol as an active ingredient. An agent of the invention for inhibiting a postprandial increase in blood insulin level contains a monoacylglycerol as an active ingredient. | 05-14-2009 |
| 20090124692 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR DECORPORATION OF RADIOACTIVE COMPOUNDS - A composition for removing a radioactive element or compound such as systemic transuranic compounds, from mammals comprises a pharmaceutical carrier and a decorporation agent comprising ester and amide derivatives of DTPA. A method of treating a mammal to remove systemic compounds utilizing the DTPA derivatives is also disclosed. | 05-14-2009 |
| 20090124693 | Cosmetic Compositions Comprising Hydroxyfatty Acids - The present invention is concerned with novel cosmetic or pharmaceutical compositions. More particularly, the invention is concerned with novel cosmetic or pharmaceutical compositions for treating or preventing any symptoms caused by negative developments of the physiological homeostasis of healthy skin, as well as for the promotion of hair growth and protection from hair loss. | 05-14-2009 |
| 20090124694 | METHOD OF PRODUCING RETINYL ESTERS - A method of producing a retinyl ester compound comprising subjecting a composition comprising retinyl or a retinyl ester and a fat or oil of animal or vegetable origins to enzyme catalysed trans-esterification in solvent free conditions to produce a retinyl ester. | 05-14-2009 |
| 20090124695 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS - A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions. | 05-14-2009 |
| 20090124696 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS - The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability. | 05-14-2009 |
| 20090124697 | Inhalation formulations of treprostinil - The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof. | 05-14-2009 |
| 20090124698 | SELECTIVE ESTROGEN RECEPTOR MODULATOR COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE - The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions. | 05-14-2009 |
| 20090124699 | Silicone Material for Releasing an Active Molecule - The invention concerns a material, preferably adhesive, for releasing an active molecule for cosmetic use or personal care or a pharmaceutically or biologically active molecule for pharmaceutical use, which is formed of a silicone substance, preferably adhesive, wherein is incorporated said molecule and a compatibility agent wherein said active molecule is soluble, said compatibility agent being selected among isopropyl myristate, isopropyl palmitate, isononyl isononanoate, neopentyl glycol dioctanoate, branched paraffins, organofunctional silicones, or a silicone oil consisting of a cyclic concatenation of 4, 5, 6 or 7 D-siloxyl units of formula: (R) | 05-14-2009 |
| 20090124700 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS - The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability. | 05-14-2009 |
| 20090124701 | USE OF ALKAMIDES FOR MASKING AN UNPLEASANT FLAVOR - An individual alkamide and/or a mixture having two or more different alkamides, is disclosed for changing, masking or reducing the unpleasant flavor impression of an unpleasant-tasting substance or mixture of substances. The alkamide can be trans-pellitorine; cis-pellitorine; 2Z,4Z- or 2Z,4E-decadienoic acid-N-isobutylamide; 2E,4E-decadienoic acid-N-([2S]-2-methylbutyl)amide; 2E,4E-decadienoic acid-N-([2R]-2-methylbutylamide); 2E,4Z-decadienoic acid-N-(2-methylbutyl)amide; achilleamide; sarmentine; 2E- or 3E-decenoic acid-N-isobutylamide; 3E-nonenoic acid-N-isobutylamide; spilanthol; homospilanthol; 2E,6Z,8E-decatrienoic acid-N-([2R]-2-methylbutyl)amide; 2E- or 2Z-decen-4-oic acid-N-isobutylamide; α-sanshool; α-hydroxysanshool; γ-hydroxysanshool; γ-hydroxysanshool; γ-hydroxyisosanshool; γ-dehydrosanshool; γ-sanshool; bungeanool; isobungeanool; dihydrobungeanool; or tetrahydrobungeanool, or combinations thereof. | 05-14-2009 |
| 20090124702 | Pharmaceutical Compositions of Metformin - The present invention relates to an extended release dosage form of highly water-soluble antidiabetic drug metformin or its pharmaceutically acceptable salts. This invention also relates to methods for preparing the extended release dosage forms of metformin or its pharmaceutically acceptable salts. | 05-14-2009 |
| 20090124703 | XANTHOHUMOL-ENRICHED HOP EXTRACT - A method for preparing a xanthohumol-rich hop composition. The method includes providing a solution that contains xanthohumol-containing hop substances and effecting precipitation of non-xanthohumol hop substances by adjusting both the salt concentration and pH value of the solution. The xanthohumol-rich hop composition prepared by this method can be used for treating various diseases, e.g., skin disorders, and bacterial infection. | 05-14-2009 |
| 20090124704 | Therapeutic foam - A foam for the treatment of varicose veins is disclosed, comprising a sclersosant solution, e.g. polidocanol, foamed with a gas mixture which includes greater than 41 % of a lipid soluble gas such as xenon. The aim is to provide a foam which may be injected into a varicose vein in large quantities because the gas component is dissipated quickly after the foam has acted on the varicose vein. | 05-14-2009 |
| 20090124705 | CARBON NANOTUBE POWDER, CARBON NANOTUBES, AND PROCESSES FOR THEIR PRODUCTION - A novel carbon nanotube powder containing carbon nanotubes which have a roll-like structure, also novel carbon nanotubes having a roll-like structure, novel processes for the production of the carbon nanotube powders and of the carbon nanotubes, and their use as an additive or substrate for various applications are described. | 05-14-2009 |
| 20090124706 | CONTACT LENS SOLUTION AND METHOD FOR HYDROPHILIZING CONTACT LENS BY USING THE SAME - It is an object of the present invention to provide a contact lens solution that imparts stable hydrophilicity even to a surface of a contact lens having strong water repellency. There was prepared a contact lens solution comprising a copolymer of N-p-vinylbenzyl-D-lactonamide and at least one monomer copolymerizable therewith. The copolymer is present in the solution in an amount of 0.0001 to 5 w/v %. | 05-14-2009 |
| 20090124707 | NONSPECIFIC ADSORPTION INHIBITOR OF SUBSTANCE RELATING TO LIVING BODY AND METHOD FOR COATING ARTICLE - a nonspecific adsorption inhibitor of a substance relating to a living body, which inhibits nonspecific adsorption of a substance relating to a living body such as various species of proteins which are used in clinical diagnostic agents, clinical diagnosis devices, biochips and the like, and a method for coating an article using said nonspecific adsorption inhibitor. | 05-14-2009 |
| 20090124708 | Collagenous tissue compositions - Implant compositions are disclosed consisting of a biocompatible carrier medium such as a saline or dextran solution and particles of collagenous material dispersed therein. The collagenous material is derived from tissue which has been milled to provide fragments of collagen fibres which preserve the architecture of the original fibres and their molecular structure. The collagenous material is also substantially free of non-fibrous tissue proteins, glycoproteins, cellular elements and lipids or lipid residues, and is non-cytotoxic. By suitable choice of particle size and concentration, the composition may be presented in injectable form or as a paste. The compositions are suitable for application in cosmetic and reconstruction surgery. | 05-14-2009 |
| 20090124709 | Analytical Methods for Validating Excipient Purity - The invention concerns methods of validating the purity of n-Dodecyl beta-D-maltoside (DDM), a membrane permeation enhancer used in nasal and oral drug delivery methods, using HPLC and Mass Spectrometry techniques. | 05-14-2009 |
| 20090124710 | Process for the Conversion of Synthesis Gas to Oxygenate - The present invention relates to an improved process for the conversion of carbon oxide(s) and hydrogen containing feedstocks to oxygen containing hydrocarbon compounds in the presence of a particulate catalyst. | 05-14-2009 |
| 20090124711 | Fischer-tropsch process and reactor assembly - A method of accommodating a reduction in production capacity of one or more reactors in a multi-reactor assembly adapted for the production of hydrocarbon products from syngas, the syngas being provided by a syngas manufacturing facility and provided to an entry stream system providing syngas to each of the reactors, and having an exit stream system taking at least hydrocarbon products from the reactors, wherein the method comprises the steps of: redistributing the syngas from the one or more said reactors to one or more other reactors, and increasing the temperature in the said one or more other reactors to at least partially take over the reduction in production capacity of the one or more reactors. | 05-14-2009 |
| 20090124712 | PROCESS FOR THE PRODUCTION OF HYBRID CATALYSTS FOR FISCHER-TROPSCH SYNTHESIS AND HYBRID CATALYST PRODUCED ACCORDING TO SAID PROCESS - Process for the production of hybrid catalysts formed by mixing two catalysts; one active in Fischer-Tropsch synthesis, the other being bifunctional. Such hybrid catalyst thus formed is active both in hydrocracking and in hydroisomerisation reactions. The present invention in addition provides obtainment of a hybrid catalyst and application thereof conjointly with FT catalysts in Fischer-Tropsch synthesis reactions. The hybrid catalyst of the present invention is capable of producing in conditions typically such as those utilised in Fischer-Tropsch synthesis branched hydrocarbons in diverse bands relating to the products thereof (for example naphtha and diesel), reducing or even eliminating necessity for a subsequent hydrotreatment stage in such synthesis reactions. Utilisation of such hybrid catalysts of the present invention prolongs the operational efficiency and working life of conventional Fischer-Tropsch synthesis catalysts, reducing substantially encapsulation of particles thereof by waxes produced in the hydroprocessing reactions. | 05-14-2009 |
| 20090124713 | Low-pressure Fischer-Tropsch process - A Fischer-Tropsch process for producing diesel fuel or diesel blending stock with a high cetane number, in a concentration of 65-90 wt % at pressures below 200 psia, using a cobalt catalyst with a rehenium and/or ruthenium promoter. The catalyst is a cobalt catalyst with crystallites having an average diameter greater than 16 nanometers, and the resulting hydrocarbon product after a rough flash, contains less than 10 wt % waxes (>C | 05-14-2009 |
| 20090124714 | POROUS RESIN PARTICLE HAVING HYDROXY GROUP OR PRIMARY AMINO GROUP AND PRODUCTION METHOD THEREOF - The present invention relates to a method for producing a porous resin particle having a functional group X, the method including: dissolving a radical polymerizable aromatic monovinyl monomer and a radical polymerizable aromatic divinyl monomer together with a polymerization initiator in an organic solvent to prepare a monomer solution, dispersing the monomer solution in water in the presence of a dispersion stabilizer to obtain a suspension polymerization reaction mixture, and performing a suspension copolymerization while adding, when 0 to 80% of the entire polymerization time of the suspension copolymerization is passed, a mercapto compound represented by the formula (I): | 05-14-2009 |
| 20090124715 | METHOD FOR PURIFYING A SOLUTION CONTAINING A PLASTIC MATERIAL - Method for purifying a solution of at least one plastic in a solvent, the said solution comprising insolubles, whereby the solution is purified using a centrifugal settler. | 05-14-2009 |
| 20090124716 | METHOD FOR PROCESSING POLYESTER WASTE - A method for processing polyester wastes, especially used polyester bottles, which comprises shredding, washing, drying and melting the waste mixture to obtain a starting raw material wherein a modifying agent selected from the group comprising a combination of polysiloxane and a plasticizer selected from the group of phthalates, or a combination of silazanes and silanes is added to the shredded and dried waste mixture, the amount of the modifying agent being 4 to 6% by weight, based on the waste mixture. | 05-14-2009 |
| 20090124717 | CARRIER FOR FLUID TREATMENT AND METHOD OF MAKING THE SAME - A foam containing 30 to 95% by weight of a polyolefin-based resin and 5 to 70% by weight of a hydrophilizing agent composed of a cellulose-based powder, the surface of the foam being in a melt fractured state. | 05-14-2009 |
| 20090124718 | POLYURETHANE FOAM - A polyurethane foam is disclosed and described. The polyurethane foam is formed by combining a first component comprising at least one polyol with a second component comprising at least one polyisocyanate. The ratio of the number of isocyanate equivalents in the second component to the number of hydroxyl equivalents in the second component is less than 1.0. The foam exhibits low levels of free diisocyanate monomer, thereby reducing the amount of hazardous, volatile organic compounds. As a result, the foam can be prepared and installed without the need for ventilation equipment, external sources of fresh air, and the like. | 05-14-2009 |
